		<u> </u>							_ 01 _1
FORM PTO-144 (REV.7-80)	ا چا	1468 9 1 713129 147	DEPARTMENT OF ENT AND TRADEM		ATTY, DOCKET NO. 51876AUSM1		PPLICATION NO. 9/912,252		
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)					APPLICANTS CROZE et al.				
					FILING DATE July 25, 2001	GROUP ART UNIT 1636			
			U.S. P	ATENT 1	DOCUMENTS		٠		
*EXAMINER INITIAL		DOCUMENT NUMBER DATE			NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
			FOREIG	N PATEN	IT DOCUMENTS				
		DOCUMENT NUMBER DATE			COUNTRY			TRANSLATION YES NO	
								125	0
	<u> </u>	<u>L.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,</u>	<u> </u>	<u> </u>					
ON	1,	Platanias, et al., "Identification of a Domain in the β Subunit of the Type I Interferon (IFN) Receptor That Exhibits a Negative Regulatory Effect in the Growth Inhibitory Action of Type I IFNs", The Journal of Biological Chemistry, Vol 273, No. 10, Issue of March 6, pp. 5577-5581, 1998.							
Qn	2.	Qin et al., "Interferon- β Gene Therapy Inhibits Tumor Formation and Causes Regression of Established Tumors in Immune-Deficient Mice", <i>Proc. Natl. Acad. Sci. USA</i> , Vol 95, pp. 14411-14416, November 1998, <i>Medical Sciences</i>							
ON	3.	Wagner et al., "Interferon Receptor Expression Regulates the Antiproliferative Effects of Interferons on Cancer Cells and Solid Tumors", Int. J. Cancer: 111,32-42 (2004).							
EXAMINER DATE CONSIDERED 5/12/05									
* EXAMINI		Initial if reference considered conformance and not conside	whether or not cri	teria is in con	formance with MPEP 609. Draw	line through			

Forms/Pat/P7-27 [01/31/01]